Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
NCT05142592 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors. The study will include a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2a). Each part will consist of a screening period of up to 28 days, a treatment period, an end of treatment visit and a safety follow-up of approximately 30 days after the last dose. IPG7236 will be given on an empty stomach (either one hour before or two hours after a meal) twice daily (approximately every 12±1 hours) in continuous 28-day cycles.
Conditions Studied
Interventions
- DRUG IPG7236
Study Locations (7)
Other
- Shanghai East Hospital — Shanghai
- Shanghai General Hospital — Shanghai
- Shanghai GoBroad Cancer Hospital China Pharmaceutical University — Shanghai
Oregon
- Providence Portland Medical Center — Portland
Texas
- NEXT Oncology — Austin
Jiangxi
- The First Affiliated Hospital Nanchang Univeristy — Nanchang
Shangdong
- Shandong Cancer Hospital — Jinan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2025-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05142592
The ClinicalTrials.gov registry entry for NCT05142592 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nanjing Immunophage Biotech Co., which has 29 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention — of which IPG7236 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05142592 reports 7 study locations spanning 5 distinct geographic areas — top geographies include Other, Oregon, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05142592 about?
NCT05142592 is a clinical study titled "Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors". This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors. The study will include a dos...
What is the current status of trial NCT05142592?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 196 participants. The study started on 2021-11-15. Estimated completion is 2025-12-21.
What conditions does trial NCT05142592 study?
This clinical trial studies the following conditions: Pharmacokinetics, Safety Issues, Tolerability. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05142592?
The interventions under investigation include: IPG7236 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05142592?
This trial is sponsored by Nanjing Immunophage Biotech Co., which has 29 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05142592 being conducted?
This trial has 7 study locations across Oregon, Texas, Jiangxi, Shangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.